학술논문
Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy
Document Type
Article
Author
Source
In: Journal of Neurology . (Journal of Neurology, 2024)
Subject
Language
English
ISSN
14321459
03405354
03405354